Etrasimod Dose-Ranging Versus Placebo as Induction Therapy inModerately to Severely Active Ulcerative Colitis
Phase 2
- Conditions
- lcerative colitis
- Registration Number
- JPRN-jRCT2071210052
- Lead Sponsor
- Tanabe Masakazu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Japanese ancestry
- Diagnosed with ulcerative colitis (UC) => 3 months prior to screening
- Having active UC confirmed by endoscopy
- Moderately to severely active UC
Exclusion Criteria
- Severe extensive colitis
- Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence, history of a fistula consistent with CD
- Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method